Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Cancer Prev Res (Phila). 2021 Mar 1;14(5):573–580. doi: 10.1158/1940-6207.CAPR-20-0598

Table 3:

Toxicity Monitoring (N= 39)

Adverse Event Grade
1 2 3 4
N % N % N % N %
Type Arm
Nausea Poly-E 2 10.5
Placebo 1 5.0
Abdominal pain Placebo 1 5.03
ALT1 increase Poly-E 13 5.3
AST2 increase Poly-E 13 5.3
Diarrhea Poly-E 1 5.3
Dizziness Placebo 1 5.0
Dyspepsia Placebo 1 5.03
Fatigue Placebo 1 5.0
Flu-like syndrome Placebo 1 5.0
Headache Placebo 1 5.0
Myalgia Placebo 1 5.0
1

Alanine aminotransferase

2

Aspartate aminotransferase;

3

same patient